Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Opendoor Technologies Inc. (NASDAQ: OPEN) is "not making any money, and, you know what, it’s one of those situations where it can continue to go higher but not for any fundamental reason, so